Alkem Laboratories Acquires 21.46% Stake in Sunsure Solarpark for Renewable Power Source

Alkem Laboratories Ltd, in continuation of their earlier intimation, has informed about the allotment of equity shares in favor of the company and its subsidiary, Enzene Biosciences Limited. This is part of a Share Subscription and Shareholders’ Agreement with M/s. Sunsure Solarpark Twenty Two Private Limited and M/s. Sunsure Energy Private Limited for an equity investment of 12.48% and 13.52% respectively. The allotment of Equity Shares in favor of Alkem Laboratories Limited and Enzene Biosciences Limited has been approved by Sunsure Solarpark. The revised shareholding in Sunsure Solarpark is as follows: Alkem Laboratories Limited holds 21.46% and Enzene Biosciences Limited holds 23.25%, making a total of 44.71%.